02.26.24 -- How To Use Precipitation, Not Protein A Chromatography, For mAb Capture

Selecting a CDMO is a long-term partnership, not just a transactional relationship, and it can impact the success of your current product and benefit the manufacturing of future products.

Explore overcoming the challenges of MSC and EV production and how bone marrow-MSC EVs with anti-inflammatory activity are being used to treat retinal degeneration and traumatic brain injuries.

An experienced contract manufacturer can help drug developers to better utilize internal resources, leverage deep industry experience, and mitigate risk across development cycles.

This e-book dissects the potency assay development process into its key steps, offering a clearer understanding of the journey.

With adjustable components and increased stability during bloodstream circulation, LNPs are significantly advancing drug development and delivery, particularly for mRNA vaccines.

This is a review of high-concentration mAb manufacturing challenges including viscosity, aggregation, instability, and the effect of excipients on formulation, filtration, fill/finish, and bioavailability.

Learn how a CDMO that is experienced in producing and characterizing diverse recombinant proteins is essential when accelerating the successful transfer of recombinant protein analytical assays.

Transposase-mediated genome engineering enables the robust and stable relocation of discrete DNA segments (transposons) in the genome, providing a valuable tool for stable transgene expression.

Review the current state of several optical technology approaches and their associated strengths and limitations along with new and transformative means to instantly implement in-line monitoring.

Review a modeling approach employing artificial neural networks using experimental factors combined with simulation-derived parameters plus viscosity data from 27 highly concentrated mAbs.

The relationship between physicochemical profile and biological activity is key to informed decisions, accelerated development, and risk reduction.

Real-time, viable environmental monitoring optimizes manufacturing timelines via immediate results, alleviates risks associated with traditional environmental monitoring, and satisfies Annex 1 regulations.

Explore this demonstration of an AAV upstream process in proprietary bioreactors, including an example of using process optimization to increase the fraction of full AAV capsids.

Explore impurities removed by strong anion exchange chromatography for the advancement of these molecules as therapeutics and a cost-effective, efficient, and scalable purification method.

Discover the challenges pharma companies are facing as they switch focus as well as the actions and technologies companies are implementing to help achieve a brighter future for patients.